Affordable Access

deepdyve-link
Publisher Website

Long-Term Efficacy of Intravitreal Conbercept Injection in the Treatment of Idiopathic Choroidal Neovascularization.

Authors
  • Wu, Peipei1
  • Shi, Depeng1
  • Chen, Xiuli1
  • Feng, Chengcheng1
  • Xu, Haifeng1
  • Lin, Ping1
  • 1 State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Shandong Eye Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Qingdao, P.R. China. , (China)
Type
Published Article
Journal
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
Publication Date
Nov 21, 2019
Identifiers
DOI: 10.1089/jop.2019.0075
PMID: 31750756
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Purpose: To investigate the long-term efficacy of intravitreal conbercept injection in treating idiopathic choroidal neovascularization (CNV). Methods: In this longitudinal retrospective cohort study, 27 eyes (27 patients) with idiopathic CNV receiving conbercept intravitreously (0.5 mg/0.05 mL) with 1+PRN regimen were included. Best corrected visual acuity (BCVA) and central retinal thickness (CRT) at the baseline and the end of follow-up were compared, respectively. The number of injections and recurrence time were evaluated. Results: Of the 27 patients, 7 were men and 20 were women. Their mean age at diagnosis was 31.37 ± 7.35 (16-46) years. The follow-up period was 44.59 ± 8.60 (27-58) months. The mean initial injection number was 1.22 ± 0.42, and 1.67 ± 1.04 injections were administered throughout the follow-up. Seven patients experienced CNV relapse, with 1 episode in 4 patients, 2 episodes in 2 patients, and 5 episodes in 1 patient. LogMAR BCVA changed from 0.77 ± 0.19 at baseline to 0.09 ± 0.10 at the final visit, and CRT decreased from 343 ± 73.5 μm to 172.41 ± 30.82 μm. Both BCVA improvement and CRT reduction were statistically significant (P < 0.001). No ocular or systemic complications occurred. Conclusions: Intravitreal injection of conbercept shows favorable effectiveness in the treatment of idiopathic CNV during a long-term period of follow-up.

Report this publication

Statistics

Seen <100 times